HHS Plans New FDA Deputy Commissioner Roles for Technology and Drugs, Sources Say

The Department of Health and Human Services is planning to establish two new deputy commissioner roles at the Food and Drug Administration, one centered on technology and another on drugs, according to sources familiar with the matter.

New Leadership Structure

The planned positions would add senior leadership to the FDA, reflecting an effort to address evolving regulatory challenges. The technology-focused deputy commissioner would oversee digital health, artificial intelligence, and other emerging tech areas, while the drug-focused role would concentrate on pharmaceutical oversight. Sources indicated that the roles are still in the planning stages and have not been formally announced.

Background

The move comes as the FDA faces increasing pressure to modernize its approach to rapidly advancing technologies and complex drug development. The agency has historically had deputy commissioners for specific areas, but these new roles would represent a targeted expansion. No timeline for the appointments or potential candidates has been disclosed.

Implications

If implemented, the new positions could streamline decision-making and enhance the FDA’s capacity to regulate cutting-edge products. The technology role, in particular, would signal a heightened focus on digital health tools and software-based medical devices. The drug-focused deputy would likely work closely with the Center for Drug Evaluation and Research.

The plans are subject to internal approval and could change before any official announcement. HHS and FDA have not commented publicly on the matter.